Amber Road Makes Market Debut; Tranzbyte Corporation Signs LOI with Abattis

Follow this company

Companies Mentioned

03/24/2014 [ACCESSWIRE]

Amber Road, Inc. (NYSE: AMBR) – For an in-depth report on Amber Road, Inc. follow:

AMBR closed up 30.77% on about 5.2 million shares traded with a closing price of $17.00 a share. Friday was the day after the company made its debut in the stock market. The leading provider of global trade management (GTM) solutions today announced the pricing of its initial public offering of 7,391,565 shares of its common stock at a price to the public of $13.00 per share.

Magnegas Corporation (NASDAQ: MNGA) - For an in-depth report on Magnegas Corporation follow:

Shares of Magnegas Corporation closed up about 60% on Friday with about 28.8 million shares traded. The stock was one of the biggest gainers on the NASDAQ and hit a new yearly high of $2.45 during intra-day trading. The company announced last week that it had received contracts for four demolition projects through existing distributors Blue Water Industrial of Michigan and AWISCO Corp of New York.

Brainstorm Cell Therapeutics Inc. (OTCBB: BCLI) - For an in-depth report on Brainstorm Cell Therapeutics Inc. follow:

BCLI closed down a modest 3% on Friday with nearly 3.6 million shares traded. The stock had one of the biggest volume boosts in the OTCBB market. The leading developer of adult stem cell technologies for neurodegenerative diseases, announced last week that Mr. Chen Schor, Executive Board Member, will present the company's latest developments at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.

Tranzbyte Corporation (OTC: ERBB) - For an in-depth report on Tranzbyte Corporation follow:

Shares of ERBB closed up 24.67% on Friday with nearly 235 million shares traded. The stock was one of the biggest gainers in the OTC market. The company announced on Friday that it has has signed a Letter of Intent to form a strategic partnership with Abattis to sell, market or otherwise license one another's products in their respective regions.


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name